2023 年 9 月 28 日，邵旻之先生取得上海证券交易所董事会秘书任职培训证 明，邵旻之先生自取得该证明之日起正式履行董事会秘书职责。 特此公告。 证券代码：600216 证券简称：浙江医药 公告编号：2023-031 浙江医药股份有限公司关于董事会秘书履职的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江医药股份有限公司（以下简称"公司"）于 2023 年 6 月 6 日下午在浙江 医药总部 1 号楼 401 会议室召开了第九届十三次董事会会议，审议通过了《关于 改聘第九届董事会董事会秘书的议案》，聘任邵旻之先生担任董事会秘书，具体 详见公司 2023 年 6 月 8 日在上海证券交易所网站（www.sse.com.cn）发布的《浙 江医药关于改聘董事会秘书的公告》（公告编号：2023-022）。 1 浙江医药股份有限公司董事会 2023 年 10 月 12 日 ...

证券代码：600216 证券简称：浙江医药 公告编号：2023-030 浙江医药股份有限公司 关于获得药物临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，浙江医药股份有限公司下属子公司浙江新码生物医药有限公司（以下 简称"公司"）收到国家药品监督管理局下发的关于公司在研药物注射用NCB003 的《药物临床试验批准通知书》，同意本品单药在晚期实体瘤开展临床试验。现 将相关情况公告如下： 一、药品基本情况 1、药物名称：注射用NCB003 2、剂型：注射剂 3、规格：1 mg/瓶 二、药品研究情况 注射用NCB003是公司自主研发的新一代定点偶联长效人白介素-2药物，拟 用于标准治疗失败的晚期恶性实体瘤，属于创新生物技术药物。 截至 2023 年 8 月，公司 NCB003 项目已累计投入研发费用 6283.21 万元人 民币（未经审计）。 三、药品的其他相关情况 白介素-2具有显著的增强免疫作用和很好的抗肿瘤临床应用潜力，国内外有 多种重组人白介素-2上市产品应用于癌症治疗。但是白介素-2在 ...

证券代码：600216 证券简称：浙江医药 公告编号：2023-029 浙江医药股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2023 年 09 月 14 日(星期四)15:00-16:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网址： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心视频直播和网络互动 （二）会议召开地点：上证路演中心 （三）会议召开方式：上证路演中心视频直播和网络互动 三、参加人员 公司副董事长、总裁吕春雷先生，独立董事裘益政先生，董事会秘书叶伟 东先生，财务总监李齐融女士。 投资者可于 2023 年 09 月 07 日(星期四)至 09 月 13 日(星期三)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 board@zmc-china.com 进行提问。公司将在说明会上对投资者普遍关注的问 题进 ...

Financial Performance - The company reported a total revenue of 33,311,713.89 RMB for the first half of 2023, with a significant contribution from non-operating income [36]. - The company's revenue for the first half of 2023 was approximately ¥3.94 billion, a decrease of 4.36% compared to the same period last year [45]. - Net profit attributable to shareholders decreased by 30.29% to approximately ¥272.26 million compared to the previous year [45]. - The net cash flow from operating activities was approximately ¥252.46 million, a significant improvement from a negative cash flow of ¥8.31 million in the same period last year [45]. - The basic earnings per share decreased by 31.71% to ¥0.28 compared to ¥0.41 in the previous year [45]. - The weighted average return on equity decreased by 1.52 percentage points to 2.88% compared to the same period last year [45]. - The company's total assets increased by 2.32% to approximately ¥12.72 billion compared to the end of the previous year [45]. - The net assets attributable to shareholders increased by 4.21% to approximately ¥9.65 billion compared to the end of the previous year [45]. - The company reported a net profit margin of 12%, reflecting improved operational efficiency [153]. Operational Highlights - The company experienced a non-operating loss from the disposal of non-current assets totaling -5,449,085.81 RMB [16]. - The company has not faced any significant operational risks during the reporting period [23]. - The company’s main business remains unchanged, focusing on life nutrition products, pharmaceutical manufacturing, and pharmaceutical commerce [37]. - The pharmaceutical commerce segment primarily involves the distribution of tendered drugs, with retail as a supplementary service [38]. - The company continues to focus on the production of life nutrition products and pharmaceutical manufacturing, including various vitamins and pharmaceutical raw materials [49]. - The company is expanding its sales of animal nutrition products primarily through self-export to Europe and the United States, as well as through domestic and international trade companies [53]. - The company has established business relationships with large dietary supplement manufacturers and major cosmetic companies for human nutrition products [53]. Financial Management - The company has established a supplier evaluation system to ensure the quality of raw materials, complying with FDA and TGA standards [38]. - The company recognizes unconditional rights to receive consideration from customers as receivables, while rights to receive consideration that depend on factors other than the passage of time are recognized as contract assets [82]. - The company applies a simplified measurement method for expected credit losses on receivables and contract assets [102]. - Long-term equity investments formed through multiple transactions are accounted for separately in individual and consolidated financial statements [85]. - The company capitalizes borrowing costs directly attributable to the acquisition or production of qualifying assets, while other borrowing costs are recognized as expenses in the current period [120]. - The company assesses impairment for long-term assets, including goodwill and intangible assets with indefinite useful lives, annually regardless of impairment indicators [125]. - The depreciation method for fixed assets is based on the straight-line method, with useful lives ranging from 5 to 40 years depending on the asset type [118]. - The company recognizes biological assets when they meet specific criteria, including reliable measurement of costs and expected economic benefits [122]. - The company has established methods for recognizing contract liabilities [126]. - The company does not apply the expected credit loss determination methods for other debt investments [83]. - The company has not applied the expected credit loss determination methods for long-term receivables [84]. Future Outlook and Strategy - The company provided an optimistic outlook for the next quarter, projecting a revenue increase of 10% to $1.65 billion [153]. - New product launches are expected to contribute an additional $200 million in revenue over the next fiscal year [153]. - The company is investing $50 million in R&D for new technologies aimed at enhancing user experience [153]. - Market expansion plans include entering three new international markets by Q4 2023, targeting a 5% increase in global market share [153]. - The company is considering strategic acquisitions to bolster its product offerings, with a budget of $100 million allocated for potential deals [153]. - A new marketing strategy is set to increase brand awareness, aiming for a 30% growth in customer engagement metrics [153]. Certification and Compliance - The company obtained the High-tech Enterprise Certificate, allowing a 15% corporate income tax rate from 2020 to 2022 [166]. - The company has received a High-tech Enterprise Certificate valid from January 1, 2021, to December 31, 2023, allowing a 15% corporate income tax rate [167]. - The company has undergone a review and received a High-tech Enterprise Certificate valid from January 1, 2022, to December 31, 2024, with a 15% corporate income tax rate [188]. Cash and Liquidity - Cash and cash equivalents stood at $300 million, providing a strong liquidity position for future investments [153]. - The company reported a total cash balance of CNY 1,507,694,005.84 at the end of the period, an increase from CNY 1,438,077,266.91 at the beginning of the period [191]. - The company has a total of CNY 1,320,098,350.67 in accounts receivable, with CNY 1,306,397,953.15 due within one year [194]. - The company has a total of CNY 258,187,425.95 in bank acceptance bills that are endorsed or discounted but not yet due [181]. - The company reported cash and cash equivalents of CNY 108,384.54 at the end of the period, up from CNY 83,589.76 at the beginning [191]. - The company has no significant doubts regarding its ability to continue as a going concern for the next 12 months [184]. Governance and Reporting - The company’s financial report has been confirmed by the board of directors for its authenticity and completeness [20]. - The company’s stock is listed on the Shanghai Stock Exchange under the code 600216 [32]. - The company’s office and registered address remain unchanged at 168 Zhiyuan Middle Avenue, Binhai New City, Shaoxing, Zhejiang [31]. - The company has specific accounting policies for financial instruments impairment, fixed asset depreciation, and income recognition [185]. - The company has not made any significant changes to its accounting policies or estimates during the reporting period [187].

证券代码：600216 证券简称：浙江医药 公告编号：2023-027 浙江医药股份有限公司关于下属生产企业新昌制药厂通过 韩国 MFDS 现场检查的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江医药股份有限公司（以下简称"公司"）下属生产企业新昌制药厂（以 下简称"新昌制药"）于 2023 年 05 月 30 日-06 月 01 日接受了来自韩国食品药 品管理局（以下简称"MFDS"）的 cGMP（现行药品生产质量管理规范）现场检 查，检查内容为盐酸万古霉素原料药日常监督检查。 2023 年 8 月 21 日，新昌制药收到 MFDS 的通知函和针对本次检查签发的现 场检查报告，确认本次检查已结束，检查结果为通过。该通知说明新昌制药的质 量管理体系符合韩国 MFDS 的标准，顺利通过了本次韩国 MFDS 的日常监督检查。 现将相关信息公告如下： 一、MFDS 现场检查的相关信息 1、企业名称：浙江医药股份有限公司新昌制药厂 4、检查范围：盐酸万古霉素 二、生产车间及生产品种 通过本次韩国 MFDS 现场检查的 ...

证券代码：600216 证券简称：浙江医药 公告编号：2023-017 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 投资者可于 2023 年 05 月 09 日(星期二)至 05 月 15 日(星期一)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 board@zmc- china.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 浙江医药股份有限公司（以下简称"公司"）已于 2023 年 04 月 26 日发布公 司 2022 年年度报告，为便于广大投资者更全面深入地了解公司 2022 年度经营成 果、财务状况，公司计划于 2023 年 05 月 16 日上午 10:00-11:00 举行 2022 年度 业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以视频结合网络互动召开，公司将针对 2022 年度经营成 果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范围 内就投资者普遍关注的问题进行回答。 二、 说 ...

Financial Performance - Total revenue for 2022 was CNY 8,115,804,648.33, a decrease of 11.10% compared to 2021[28]. - Net profit attributable to shareholders was CNY 539,570,083.23, down 48.38% from the previous year[28]. - The company reported a net cash flow from operating activities of CNY 520,603,490.03, a decline of 54.20% year-on-year[28]. - The total assets at the end of 2022 were CNY 12,432,616,205.07, a decrease of 0.80% from the previous year[28]. - The net assets attributable to shareholders increased by 5.48% to CNY 9,259,881,857.33[28]. - The overall operating income decreased by 11.10% to CNY 8,115,804,648.33 compared to the previous year[81]. - Basic earnings per share decreased by 48.62% to CNY 0.56 in 2022 from CNY 1.09 in 2021[129]. - Diluted earnings per share also fell by 48.62% to CNY 0.56 in 2022 compared to CNY 1.09 in 2021[129]. - The weighted average return on equity dropped by 6.65 percentage points to 5.99% in 2022 from 12.64% in 2021[129]. Research and Development - R&D expenses totaled CNY 809,279,317.22, accounting for 9.97% of total revenue[17]. - The company applied for 24 patents during the reporting period, including 21 invention patents, and has a total of 686 invention patent applications as of December 31, 2022[48]. - The company reported a total R&D investment of 15,664 million RMB for the anti-Her2-ADC project, which accounted for 1.93% of total revenue, reflecting a decrease of 15.47% compared to the previous year[169]. - The R&D investment for the innovative research on key intermediates of raw materials reached 2,297 million RMB, showing a significant increase of 890.21% compared to the previous year[169]. - The company has a strong focus on ensuring that intangible assets can generate economic benefits, supported by sufficient technical and financial resources[158]. - The company follows a research and development accounting policy where expenses during the research phase are recognized in the current period, while development phase expenses can be recognized as intangible assets if certain criteria are met[158]. Sales and Marketing - The company's sales revenue for life nutrition products reached CNY 384,105.80 million, accounting for 47.33% of total revenue, a year-on-year decrease of 18.91%[75]. - Pharmaceutical manufacturing generated sales of CNY 201,622.05 million, representing 24.84% of total revenue, with a year-on-year decline of 3.00%[75]. - Pharmaceutical commerce achieved sales of CNY 213,660.98 million, making up 26.33% of total revenue, down 4.99% year-on-year[75]. - The company has established a comprehensive marketing network covering over 25,000 pharmacies, achieving effective coverage in all provinces except Tibet[183]. - The company’s marketing strategy emphasizes compliance and efficiency, aiming to enhance product sales through scientific marketing methods[175]. - The company has established long-term partnerships with major pharmaceutical companies for raw material exports, ensuring stable sales channels[182]. Production and Operations - The company is advancing the production of vitamin E precursor projects, achieving self-sufficient production of key raw materials by the end of 2022[47]. - The company has implemented a safety production management system and established a "no waste park" initiative to enhance operational efficiency[45]. - The company is focusing on enhancing its product structure and industry chain layout in response to market challenges[47]. - The company is transitioning to "Industry 4.0" in the pharmaceutical sector, implementing modern and digital control systems in production[68]. - The company has established long-term strategic partnerships with reputable domestic and international distributors, enhancing its marketing network[68]. Market Trends and Challenges - The company has made significant advancements in the vitamin industry, despite challenges such as rising costs and decreased demand in the feed and breeding sectors[51]. - The sales of the main products, such as Vitamin E and A, have declined due to international market conditions and price drops[76]. - The company is actively responding to regulatory changes aimed at accelerating the approval process for innovative drugs, which could positively impact future product launches[135]. Investments and Acquisitions - The total investment amount for the reporting period was 346.30 million RMB, representing an increase of 91.14 million RMB or 35.72% compared to the previous year's investment of 255.16 million RMB[192]. - The company increased its capital in Fangyuanxin Biological by 200 million RMB, raising its registered capital from 50 million RMB to 250 million RMB[192]. - The company acquired 100% equity of Shilitaihe for 6.3 million RMB, completing the transfer of control by May 31, 2022[192]. - The company is focused on expanding its investments in biotechnology and pharmaceuticals, as evidenced by the capital increases in its subsidiaries[192]. - The company is actively pursuing strategic acquisitions to enhance its market position and technological capabilities[192].

Financial Performance - The net profit for Q1 2023 was CNY 84,072,216.08, a decrease of 60.9% compared to CNY 214,844,440.33 in Q1 2022[17] - The total revenue for Q1 2023 was CNY 105,302,495.52, down from CNY 268,017,651.01 in the same period last year, indicating a decline of 60.7%[17] - The total comprehensive income for Q1 2023 was CNY 85,331,152.98, down from CNY 210,743,400.09 in Q1 2022[17] - The net profit attributable to shareholders was ¥113,551,849.15, down 56.42% year-over-year, primarily due to a significant decline in the selling price of the main product, VA[24] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥98,141,772.45, a decrease of 61.55% compared to the previous year[20] - The basic and diluted earnings per share were both ¥0.12, reflecting a decline of 55.56% year-over-year[20] - The comprehensive income attributable to the parent company's owners was ¥114,760,535.24, down from ¥256,763,499.85 in the same period last year[34] Shareholder Information - The company reported a total of 68,061 common shareholders at the end of the reporting period[9] - The total number of shares held by the largest shareholder, New Changxing Changxin Investment Development Co., Ltd., was 208,192,361, representing 21.57% of total shares[9] Assets and Liabilities - The total liabilities amounted to CNY 2,660,022,342.62, a slight decrease from CNY 2,722,757,157.71 in the previous period[15] - The total equity attributable to shareholders of the parent company was CNY 9,401,601,058.23, an increase from CNY 9,259,881,857.33[15] - The total current assets as of March 31, 2023, amounted to CNY 5,607,508,474.35, slightly down from CNY 5,654,960,631.32 at the end of 2022[40] - The total non-current assets increased to CNY 6,875,763,833.60 from CNY 6,777,655,573.75 at the end of 2022[41] - The total assets reached CNY 12,483,272,307.95, up from CNY 12,432,616,205.07 at the end of 2022[41] Cash Flow - The net cash flow from operating activities increased by 111.26% to ¥19,934,634.67, mainly due to a reduction in payments for raw materials[24] - In Q1 2023, the cash inflow from operating activities was CNY 1,923,099,171.73, a decrease of 7.04% from CNY 2,068,968,525.42 in Q1 2022[35] - The net cash flow from operating activities was CNY 19,934,634.67, compared to a net outflow of CNY -177,050,453.00 in the same period last year[48] - The cash outflow from investing activities was CNY 493,879,019.83, down from CNY 583,112,675.51 in Q1 2022[48] - The cash flow from financing activities resulted in a net outflow of CNY -7,214,513.92, compared to a net inflow of CNY 71,569,874.78 in the same period last year[48] - The company reported a decrease in cash received from operating activities, with a drop of CNY 133,769,353.69 compared to the previous year[48] - The company’s cash flow from investment activities showed a significant improvement, with a reduction in net outflow by CNY 214,484,790.54 year-over-year[48] Accounting Standards and Compliance - Zhejiang Pharmaceutical Co., Ltd. will implement new accounting standards starting in 2023, affecting the financial statements from the beginning of the year[50] - The board of directors announced the financial report on April 25, 2023, indicating a commitment to transparency and compliance with updated regulations[51] - The company is focused on enhancing its financial reporting practices to align with the latest accounting guidelines[50] - There are no adjustments reported for the first execution year of the new accounting standards, indicating stability in financial reporting[50] - The company aims to maintain its market position while adapting to new regulatory requirements[51] - Future financial outlook remains cautiously optimistic as the company navigates the changes in accounting standards[50] - The board emphasizes the importance of accurate financial data in strategic decision-making processes[51] - The implementation of new standards is expected to improve the overall quality of financial disclosures[50] - The company is committed to ongoing evaluation of its financial practices to ensure compliance and accuracy[51] - No significant changes in user data or market expansion strategies were disclosed during the call[51]

Financial Performance - The company's operating revenue for Q3 2022 was ¥2,006,205,112.46, a decrease of 8.56% compared to the same period last year[7]. - The net profit attributable to shareholders for Q3 2022 was ¥93,866,572.27, down 61.37% year-on-year[7]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥57,410,371.09, a decline of 70.88% compared to the previous year[7]. - The basic earnings per share for Q3 2022 was ¥0.10, reflecting a decrease of 60.00% year-on-year[10]. - The diluted earnings per share for Q3 2022 was also ¥0.10, down 60.00% from the same period last year[10]. - Total operating revenue for the first three quarters of 2022 was CNY 6,123,873,142.30, a decrease of 10.1% compared to CNY 6,811,651,988.14 in the same period of 2021[30]. - Net profit for the third quarter of 2022 was CNY 357,899,312.31, a decline of 47.8% from CNY 685,910,072.56 in the same quarter of 2021[33]. - Total comprehensive income for the period attributable to the parent company was CNY 482,860,926.55, down from CNY 742,419,297.12 in the same period last year, representing a decrease of approximately 34.9%[35]. - Basic and diluted earnings per share were both CNY 0.51, compared to CNY 0.78 in the previous year, reflecting a decline of 34.6%[35]. Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date was ¥141,215,952.32, a decrease of 68.84% compared to the previous year[10]. - Cash inflow from operating activities totaled CNY 6,410,825,337.82, down from CNY 7,051,753,669.29, a decline of approximately 9.1%[39]. - Cash outflow from operating activities was CNY 6,269,609,385.50, compared to CNY 6,598,619,416.76 in the previous year, showing a decrease of about 5%[39]. - The ending cash and cash equivalents balance was CNY 1,304,784,270.68, down from CNY 1,632,665,283.12, reflecting a decrease of approximately 20%[41]. - The company reported a tax refund of CNY 321,071,190.31, compared to CNY 213,805,121.98 in the previous year, marking an increase of about 50.1%[39]. Assets and Liabilities - Total assets at the end of the reporting period were ¥12,370,875,396.96, a decrease of 1.29% from the end of the previous year[10]. - The company's current assets totaled CNY 5,658,885,465.86, down from CNY 6,034,823,006.11, indicating a decrease of about 6.19%[25]. - Cash and cash equivalents were reported at CNY 1,304,784,270.68, a significant decrease from CNY 1,768,531,510.26, reflecting a decline of approximately 26.30%[21]. - The company's total liabilities decreased to CNY 5,658,885,465.86 from CNY 6,034,823,006.11, indicating a decline of approximately 6.19%[25]. - The company's total liabilities decreased to CNY 2,707,415,382.53 from CNY 3,349,948,357.08, indicating a reduction of 19.2%[28]. - The total equity attributable to shareholders increased to CNY 9,165,509,080.53, up from CNY 8,779,106,085.10, representing a growth of 4.4%[28]. - The minority interest increased to CNY 497,950,933.90 from CNY 402,925,398.05, reflecting a growth of 23.5%[30]. - The company's deferred income tax liabilities decreased to CNY 10,998,703.64 from CNY 20,830,017.00, a reduction of 47.3%[28]. Research and Development - The company reported a significant increase in new drug R&D expenses during the quarter, contributing to the decline in net profit[14]. - Research and development expenses for the first three quarters of 2022 were CNY 555,393,836.63, down 19.8% from CNY 692,647,517.23 in the same period of 2021[30]. - The company has no significant new product launches or technological developments reported during the quarter[19]. Operational Costs - Total operating costs for the first three quarters of 2022 were CNY 5,498,607,942.85, down from CNY 5,966,861,959.15, reflecting a reduction of 7.8%[30]. - The company reported a financial expense of CNY -37,178,071.08, compared to CNY 51,751,856.25 in the previous year, indicating a significant improvement[30].

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 4,117,668,029.84, a decrease of 10.83% compared to CNY 4,617,544,128.15 in the same period last year[25]. - The net profit attributable to shareholders of the listed company was CNY 390,587,728.16, down 23.06% from CNY 507,621,136.65 in the previous year[25]. - The net profit after deducting non-recurring gains and losses was CNY 380,737,753.77, a decrease of 18.35% compared to CNY 466,291,760.87 in the same period last year[25]. - The net cash flow from operating activities was negative CNY 8,310,209.08, a significant decline from CNY 458,457,262.86 in the previous year, representing a decrease of 101.81%[25]. - The total assets at the end of the reporting period were CNY 12,330,384,792.90, down 1.61% from CNY 12,531,979,840.23 at the end of the previous year[25]. - Basic earnings per share for the first half of 2022 were CNY 0.41, a decrease of 22.64% from CNY 0.53 in the same period last year[25]. - The weighted average return on net assets was 4.40%, down 1.94 percentage points from 6.34% in the previous year[25]. - The company reported a significant increase in sales of its star product, lutein chewable tablets, indicating strong growth in innovative health products[45]. Research and Development - The company has applied for 8 invention patents during the reporting period, with 3 domestic invention patents granted, bringing the total to 671 applied and 276 effective patents, including 94 international patents[44]. - The company has successfully completed the production process verification for the active pharmaceutical ingredient of moxifloxacin and has commenced normal production of both moxifloxacin and natural vitamin E since June 2022[46]. - The company is advancing the development of its biopharmaceutical ARX788, with over 100 cases enrolled in clinical trials for gastric cancer as of May 2022[45]. - The company reported a significant reduction in research and development expenses to CNY 355,076,062.82 from CNY 545,351,850.09, a decrease of 34.83%[150]. Market and Industry Position - The main business remains unchanged, focusing on life nutrition products, pharmaceutical manufacturing, and pharmaceutical commerce, with key products including synthetic vitamins E and A, and antibiotic raw materials[29]. - The pharmaceutical industry is expected to maintain stable growth despite challenges from the pandemic and geopolitical issues, with the company positioned to leverage its technological advancements and strong market presence[34]. - The company aims to enhance its core competitiveness through innovation, structural adjustments, and the establishment of a robust marketing network with long-term partnerships[37]. - The company’s pharmaceutical commerce segment primarily targets public hospitals, leveraging a standardized operation to gain market share[32]. Challenges and Risks - The company has faced increased logistics costs due to the pandemic, impacting supply chains and market demand[34]. - The company is facing risks related to rising production costs due to international transportation cost increases and raw material price surges caused by geopolitical tensions[71]. - The company emphasizes the importance of policy changes in the pharmaceutical industry, which significantly affect its operations and strategies[67]. - The company has established a COVID-19 response plan to ensure employee health and maintain orderly production operations amid ongoing pandemic challenges[71]. Environmental and Sustainability Initiatives - The company is committed to sustainable practices, including clean production and circular economy initiatives, to strengthen its market position globally[37]. - The company has implemented pollution control measures, ensuring all facilities are operating normally and achieving stable compliance with discharge standards[88]. - The company has introduced a hazardous waste incineration facility to reduce waste generation and lower energy consumption through resource utilization[88]. - The company is actively promoting energy conservation and carbon reduction initiatives, aligning with national policies on "dual control of energy consumption" and "carbon neutrality"[98]. Shareholder and Capital Management - The company did not propose any profit distribution plan or capital reserve transfer to increase share capital during the reporting period[7]. - The company launched a second phase of a restricted stock incentive plan, granting 6.8275 million shares to 495 incentive targets, aimed at attracting and retaining talent[49]. - The company approved the second phase of the restricted stock incentive plan at the extraordinary shareholders' meeting on January 20, 2022[78]. - The company reported a profit distribution of CNY -318,492,240.00 during the period[179]. Financial Position and Equity - The total owner's equity at the end of the period was CNY 9,333,967,729.87, reflecting an increase from the previous period[196]. - The total comprehensive income for the period amounted to CNY 478,849,806.37[193]. - The total capital stock remained unchanged at CNY 965,128,000.00 throughout the period[182]. - The total liabilities decreased to CNY 2,251,962,583.25 from CNY 2,320,042,743.61, indicating a reduction of 2.94%[148].